Plant Name: Lycopus europaeus
Taxonomic Information:
Plant ID: NPO12357
Plant Latin Name: Lycopus europaeus
Taxonomy Genus: Lycopus
Taxonomy Family: Lamiaceae
Plant External Links:
NCBI TaxonomyDB:
260603
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
China; IndiaTraditional Medicine System:
Indian Folk; TCMMedicinal Functions:
Astringent; Miscellany; Poultice; Sedative
Geographical Distribution:
India; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| RECQL; TDP1; PKM; HSD11B1; HSD17B1; ALOX15; NOX4; APEX1; POLB; | |
| CDC25B; | |
| FLT3; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA14; CA7; CA4; | |
| RORC; | |
| NR1H4; | |
| ESR2; | |
| MMP12; MMP1; MMP2; MMP9; | |
| F2; | |
| HIF1A; NFKB1; | |
| THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.236E-12 | 6.731E-09 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.220E-11 | 1.313E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.396E-10 | 1.611E-06 | CA1, CA12, CA2, CA4, CA7, CA9, ESR2, MMP1, MMP12, MMP2, MMP9, NR1H4, RORC |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.681E-08 | 2.615E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 7.723E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 4.545E-07 | 3.299E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.483E-07 | 4.412E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.289E-06 | 7.584E-04 | HIF1A, MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.674E-06 | 1.388E-03 | APEX1, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, RORC |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.849E-06 | 1.443E-03 | ALOX15, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD17B1, NOX4, PKM |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.190E-06 | 1.543E-03 | APEX1, POLB |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.270E-06 | 1.548E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.994E-06 | 1.850E-03 | CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, FLT3, NFKB1, NR1H4, RORC |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 4.895E-06 | 2.050E-03 | ACHE, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, FLT3, HIF1A, HSD11B1, PKM, POLB |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.653E-06 | 2.316E-03 | MMP1, MMP12, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.088E-06 | 2.806E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0009967; positive regulation of signal transduction | 8.044E-06 | 3.128E-03 | ALOX15, CSNK2A1, CYP1B1, F2, FLT3, HIF1A, MMP12, MMP9, NFKB1, NOX4, NR1H4, THPO |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 8.721E-06 | 3.332E-03 | ALOX15, APEX1, CA2, CA9, CYP1B1, HIF1A, MMP9, NFKB1, NOX4, POLB, RECQL, TDP1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 3.412E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.558E-06 | 3.412E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.727E-06 | 3.416E-03 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.232E-05 | 3.996E-03 | MMP1, MMP12, MMP2, MMP9 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.726E-05 | 5.293E-03 | ESR2, HSD17B1, NR1H4, RORC |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.850E-05 | 5.595E-03 | APEX1, CA2, CA9, CSNK2A1, CYP1A2, FLT3, NFKB1, PKM |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 5.619E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 2.033E-05 | 5.903E-03 | ALOX15, CYP1A1, CYP1A2, CYP1B1, HIF1A, NR1H4, PKM |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.092E-05 | 5.933E-03 | CDC25B, CSNK2A1, F2, FLT3, HIF1A, MMP12, MMP2, MMP9, THPO |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.154E-16 | 4.691E-12 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.092E-16 | 5.347E-14 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.933E-10 | 3.640E-08 | HSD11B1, HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.709E-06 | 5.981E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.850E-06 | 2.061E-04 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.873E-05 | 7.708E-04 | FLT3, MMP1, MMP2, HIF1A, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.247E-05 | 2.620E-04 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.640E-05 | 7.500E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.000E-05 | 7.500E-04 | MMP1, MMP2, MMP9 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.178E-04 | 2.541E-03 | PKM, FLT3, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.864E-04 | 7.021E-03 | MMP2, MMP9, ESR2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 7.355E-04 | 7.021E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | FLT3; HIF1A; MMP9; PKM; MMP2; F2; CA9; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; HSD11B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; MMP9; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F2; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F2; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F2; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | F2; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F2; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CYP19A1; CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; MMP9; MMP2; F2; CDC25B; CA1; CA9; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; CA1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | F2; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| NA: NA | Edema | NA | CA2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | F2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F2; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; PKM; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
